Evidence map›Paper›PMID 40192901›Full record

ReviewCurrent cardiology reports2025

Cardiovascular Risk Associated with the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults.

Aditi Kothari, John Paul Aparece, Raul Del Toro Mijares

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Aditi KothariDivision of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA. adikotha@ttuhsc.edu.
John Paul ApareceDivision of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.
Raul Del Toro MijaresDivision of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThe increasing prevalence of attention deficit hyperactivity disorder (ADHD) makes it important to study the cardiovascular implications of this disease and the drugs used to treat it. As more patients are diagnosed with ADHD across the world and these medications are prescribed more, it is imperative to understand the cardiovascular risk profile associated with these medications. This narrative review will highlight the importance of considering cardiovascular risk factors inherent to ADHD and the medications currently used to treat it. RECENT

findingsChronic sympathetic activation as caused by ADHD therapies has numerous effects on the cardiovascular system including an increase in blood pressure and heart rate. These changes could potentially lead to heart failure, arrythmias or even sudden cardiac death. While a few studies that have shown no correlation between ADHD medications and cardiovascular effects, current guidelines recommend a thorough assessment prior to initiating treatment and periodic monitoring during treatment.

Indexed as

Attention Deficit Disorder with HyperactivityCardiovascular DiseasesCentral Nervous System StimulantsAdultBlood PressureHeart Disease Risk FactorsHeart RateHumansRisk FactorsCentral Nervous System StimulantsADHDAttention-deficit/hyperactivity disorderCardiac side effectsCardiovascular effects

Identifiers

PMID40192901

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.